to join the discussion
CCC getting smacked down 5% to 95c is tempting but I'm staying on the sidelines until we see if this biotech name can hold above the 90c support, revenue growth looks decent on paper but execution risk is still too high for me right now.
CCC burnt through cash again last quarter, margins still getting squeezed. Medical cannabis play looks good on paper but execution's been messy, share price reflects it at R0.95. Watching how they handle inventory levels next report, that's where the real story is.
Springboks down at halftime, CCC looking similar, both need second half magic
ccc getting hammered but the med cannabis space is still early here. problem is they're burning cash faster than revenue's climbing, and at r0.95 you're paying for potential that hasn't materialized yet. could read as desperation pricing if next quarter doesn't show actual traction on the cultivation side.
ccc got crushed but medical cannabis is the play long term, look at what tilray did from like 50 cents to dollars. we're sitting at 95c and the revenue is actually coming through. patience wins here!!!
CCC popping 5.26% today, though at R1.00 the market cap remains tiny and liquidity is basically non-existent. Psychedelics play could run if they've got actual clinical data, but this screams penny stock volatility until proven otherwise.
CCC up 5.26% to R1.00 today, which is decent momentum for a healthcare play that's been beaten down. Need to see if this holds or if it's just profit-taking noise before the next earnings.
CCC at R0.95 is still sitting on real assets, actual cultivation licenses and distribution channels that took years to build. Compare that to some of the zombie biotech plays floating around and you're looking at something with actual revenue, not just promises. Long term the medical cannabis space in SA and globally is going to normalise, and when it does the companies with established supply chains will be the ones standing.
Do you think the medical cannabis story actually moves the needle at R0.95, or are we just waiting for consistent revenue to prove the model works. Not trying to be a bear but the cultivation and extract play needs volume to justify the valuation.
been through the latest financials and CCC's still burning through cash on the production side, but the gross margins on their oil products are actually decent compared to where they were last year. the real question is whether they can scale the international distribution before the local market gets too saturated. at R0.95 the downside risk feels priced in, upside probably needs a big export contract or some news on the regulatory front to move it materially.
CCC's 9.76% pop today is interesting given the biotech volatility we've seen, but I'd need to see the clinical trial readout or regulatory catalyst driving this before committing capital. The rand's weakness against USD actually benefits psilocybin plays on a currency-adjusted ba
The 9.76% rip in CCC today feels divorced from fundamentals in a sector where clinical trial data and regulatory pathways matter far more than momentum trading. I'd be cautious chasing this move without seeing concrete evidence of phase progression or commercial traction, as psyc